以p16INK4a为媒介的细胞衰老作为FLT3-ITD驱动的急性髓性白血病的治疗策略
Jiarui Zheng1,2, Linlin Jin1,2, Yunlong Chen1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
在急性髓性白血病 (AML) 中FLT3- ITD突变抑制瘤抑制剂p16INK4a,导致衰老逃避和更糟糕的患者结果. 针对这种途径为FLT3-ITDAML提供了新的治疗策略.
科学领域:
- 癌症学
- 分子生物学
- 癌症遗传学
背景情况:
- 细胞衰老是一个关键的瘤抑制机制.
- 在FLT3-ITD阳性的急性髓性白血病 (AML) 中,衰老的作用尚不清楚.
- FLT3- ITD突变在AML中很常见,并且与预后不佳有关.
研究的目的:
- 调查p16INK4a在FLT3-ITD阳性的AML中的作用.
- 阐明FLT3-ITD影响p16INK4a表达的分子机制.
- 为了确定FLT3-ITDAML的潜在治疗点.
主要方法:
- 从FLT3-ITDAML患者的多个测序数据集的分析.
- 对于 FLT3-ITD AML 的淘汰小鼠模型.
- 对STAT5A-E2F3-EZH2信号轴进行调查.
主要成果:
- 在FLT3- ITDAML患者中,低p16INK4a表达与预后明显差.
- 在小鼠中,p16INK4a淘汰加速FLT3-ITDAML的发病.
- FLT3-ITD通过STAT5A-E2F3-EZH2途径抑制p16INK4a,促进衰老逃避和恶性瘤.
- 一个积极的反循环加剧了疾病的进展.
结论:
- FLT3-ITD-STAT5A/E2F3/EZH2-p16INK4a轴解释了FLT3-ITDAML患者的一个小组的低生存率.
- 这一轴对具有低p16INK4a表达的耐火FLT3- ITDAML具有前途的治疗点.
更多相关视频
08:56Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
13:59A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence
Published on: August 12, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Replicative Cell Senescence
Inhibition of Cdk Activity
Abnormal Proliferation
